Compare TFX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFX | WGS |
|---|---|---|
| Founded | 1943 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.6B |
| IPO Year | N/A | N/A |
| Metric | TFX | WGS |
|---|---|---|
| Price | $109.97 | $138.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $139.88 | $138.13 |
| AVG Volume (30 Days) | ★ 732.0K | 382.0K |
| Earning Date | 02-26-2026 | 02-17-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $3,189,988,000.00 | $402,190,000.00 |
| Revenue This Year | $9.90 | $41.17 |
| Revenue Next Year | $10.51 | $23.53 |
| P/E Ratio | ★ N/A | $1,869.35 |
| Revenue Growth | 5.42 | ★ 50.50 |
| 52 Week Low | $102.58 | $55.17 |
| 52 Week High | $185.94 | $170.87 |
| Indicator | TFX | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 33.05 | 48.02 |
| Support Level | $108.39 | $124.26 |
| Resistance Level | $127.49 | $138.73 |
| Average True Range (ATR) | 3.05 | 5.52 |
| MACD | -1.50 | 0.23 |
| Stochastic Oscillator | 10.79 | 69.60 |
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.